Form 4: CGON Director Sells Shares After Option Exercise

CG Oncology Director James Mulay exercised stock options and subsequently sold the acquired common stock in pre-planned transactions on September 18 and 19, 2025.

Summary

• James Mulay, a Director of CG Oncology, Inc. (CGON), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• On September 18, 2025, Mulay exercised options to acquire 19,112 shares of common stock at an exercise price of $1.82 per share.
• Immediately following the option exercise on September 18, 2025, he sold all 19,112 shares at a weighted average price of $39.01 per share, with prices ranging from $38.99 to $39.12.
• On September 19, 2025, Mulay exercised options to acquire an additional 3,574 shares of common stock at an exercise price of $1.82 per share.
• Concurrently on September 19, 2025, he sold all 3,574 shares at a price of $38.99 per share.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 6, 2025.
• Following these transactions, Mulay beneficially owns 16,329 Director Stock Options from the first transaction and 12,755 Director Stock Options from the second transaction, which are fully vested and expire on July 18, 2031.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (exercise of vested stock options and subsequent sale of common stock) executed under a pre-arranged Rule 10b5-1 trading plan. These transactions are common for directors managing their equity compensation and do not inherently signal positive or negative sentiment about the company's operational performance or future prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned rather than reactive sale.
• The sale prices of $39.01 and $38.99 per share are significantly higher than the exercise price of $1.82 per share, indicating a substantial gain for the director.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors, though in this context, it is a routine liquidity event for vested options.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports routine insider transactions and does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• This Form 4 filing reports standard insider transactions (option exercise and sale) which are common for executives and directors to manage their equity compensation and personal finances.
• The use of a Rule 10b5-1 trading plan is a standard practice to mitigate concerns about insider trading by pre-scheduling transactions.

Stakeholder Impact

• The transactions represent a routine liquidity event for a director and are unlikely to have a direct material impact on shareholders, employees, customers, suppliers, or creditors.
• The sale of shares by a director could be perceived by some as a slight negative, but the pre-planned nature under Rule 10b5-1 mitigates this.

Key Dates

Keywords

CG Oncology, CGON, James Mulay, Form 4, insider trading, stock options, Rule 10b5-1, equity sales, director transactions, beneficial ownership